PTEN, a unique tumor suppressor gene

Endocrine-Related Cancer

Volumn 7, Issue 2, 2000, Pages 115-129

  Dahia, P L M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CAENORHABDITIS ELEGANS; CELL CYCLE; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE STRUCTURE; KNOCKOUT MOUSE; MOLECULAR CLONING; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STRUCTURE ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 0033856110     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0070115     Document Type: Article

References (102)

1. Albarosa R, Colombo BM, Roz L, Magnani I, Pollo B, Cirenei N, Giani C, Conti AMF, DiDonato S & Finocchiaro G 1996 Deletion mapping of gliomas suggests the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. American Journal of Human Genetics 58 1260-1267.
2. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB & Cohen P 1997 Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Current Biology 7 261-269.
3. Ali IU, Schriml LM & Dean M 1999 Mutational spectra of PTEN/ MMAC1 gene: a tumor suppressor with lipid phosphatase activity. Journal of the National Cancer Institute 91 1922-1932.
4. Balendran A, Casamayor A, Deak M, Paterson A, Gaffney P, Currie R, Downes CP & Alessi DR 1999 PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Current Biology 9 393-404.
5. Bose S, Wang SI, Terry MB, Hibshoosh H & Parsons R 1998 Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17 123-127.
6. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J & Greenberg ME 1999 AKT promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 857-868.
7. Caffrey JJ, Hidaka K, Matsuda M, Hirata M & Shears SB 1999 The human and rat forms of multiple inositol polyphosphate phosphatase: functional homology with a histidine acid phosphatase up-regulated during endochondral ossification. FEBS Letters 442 99-104.
8. Caims P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS & Sidransky D 1997 Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Research 57 4997-5000.
9. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, Bose S, Wang SI, Parsons R & Sidransky D 1998 Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 16 3215-3218.
10. Cantley LC & Neel BG 1999 New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. PNAS 96 4240-4245.
11. Chen J, Lindblom P & Lindblom A 1998 A study of the PTEN/ MMAC1 gene in 136 breast cancer families. Human Genetics 102 124-125.
12. Cheney IW, Neuteboom ST, Vaillancourt MT, Ramachandra M & Bookstein R 1999 Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cancer Research 59 2318-2323.
13. Chi H, Tiller GE, Dasouki MJ, Romano PR, Wang J, O'Keefe RJ, Puzas JE, Rosier RN & Reynolds PR 1999 Multiple inositol polyphosphate phosphatase: evolution as a distinct group within the histidine phosphatase family and chromosomal localization of the human and mouse genes to chromosomes 10q23 and 19. Genomics 56 324-336.
14. Coffer PJ, Jin J & Woodgett JR 1998 Protein kinase B (c-AKT): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochemical Journal 335 1-13.
15. Cross DA, Alessi DR, Cohen P, Andjelkovich M & Hemmings BA 1995 Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 785-789.
16. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C & Eng C 1997 Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Research 57 4710-4713.
17. Dahia PL, FitzGerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, von Deimling A, Haluska FG, Haber DA & Eng C 1998 A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene 16 2403-2406.
18. Dahia PLM, Aguiar RCT, Alberta J, Kum JB, Caron S, Sill H, Marsh DJ, Ritz J, Freedman A, Stiles C & Eng C 1999 PTEN is inversely correlated with the cell survival factor AKT/PKB and is inactivated via multiple mechanisms in haematological malignancies. Human Molecular Genetics 8 185-193.
19. Dahia PLM, Gimm O, Chi H, Marsh DJ, Reynolds PR & Eng C 2000 Absence of germline mutations in MINPP1, a phosphatase-encoding gene centromeric of PTEN, in patients with Cowden and Bannayan-Riley-Ruvalcaba syndrome without germline PTEN mutations. Journal of Medical Genetics (In Press).
20. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y & Greenberg ME 1997 AKT phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 231-241.
21. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J & Dedhar S 1998 Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. PNAS 95 11211-11216.
22. Di Cristofano A, Pesce B, Cordon-Cardo C & Pandolfi PP 1998 PTEN is essential for embryonic development and tumour suppression. Nature Genetics 19 348-355.
23. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB & Pandolfi PP 1999 Impaired fas response and autoimmunity in Pten(+/-) mice. Science 285 2122-2125.
24. Diehl JA, Cheng M, Roussel MF & Sherr CJ 1998 Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes and Development 12 3499-3511.
25. Eng C 1997 Cowden syndrome. Journal of Genetic Counseling 6 181-191.
26. Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboue B, Latham WC, Eng C, Mulligan LM & Longy M 1999 Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. British Journal of Cancer 79 718-723.
27. FitzGerald MG, Marsh DJ, Wahrer D, Bell D, Caron S, Shannon KE, Ishioka C, Isselbacher KJ, Garber JE, Eng C & Haber DA 1998 Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene 17 727-731.
28. Furnari FB, Lin H, Huang HS & Cavenee WK 1997 Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. PNAS 94 12479-12484.
29. Furnari FB, Huang HJ & Cavenee WK 1998 The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Research 58 5002-5008.
30. Georgescu MM, Kirsch KH, Akagi T, Shishido T & Hanafusa H 1999 The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. PNAS 96 10182-10187.
31. Gil EB, Malone Link E, Liu LX, Johnson CD & Lees JA 1999 Regulation of the insulin-like developmental pathway of Caenorhabditis elegans by a homolog of the PTEN tumor suppressor gene. PNAS 96 2925-2930.
32. Gronbaek K, Zeuthen J, Guldberg P, Ralfkiaer E & Hou-Jensen K 1998 Alterations of the MMAC1/PTEN gene in lymphoid malignancies (letter). Blood 91 4388-4390.
33. Gu J, Tamura M & Yamada KM 1998 Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. Journal of Cell Biology 143 1375-1383.
34. Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K & Yamada KM 1999 She and FAK differentially regulate cell motility and directionality modulated by PTEN. Journal of Cell Biology 146 389-403.
35. Halachmi N, Halachmi S, Evron E, Cairns P, Okami K, Saji M, Westra WH, Zeiger MA, Jen J & Sidransky D 1998 Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes, Chromosomes and Cancer 23 239-243.
36. Jacoby RF, Schlack S, Cole CE, Skarbek M, Harris C & Meisner LF 1997 A juvenile polyposis tumor suppressor locus at 10q22 is deleted from nonepithelial cells in the lamina propria. Gastroenterology 112 1398-1403.
37. Kobayashi H, Hosoda F, Maseki N, Sakurai M, Imashuku S, Ohki M & Kaneko Y 1997 Hematologic malignancies with the t(10;11) (p13;q21) have the same molecular event and a variety of morphologic or immunologic phenotypes. Genes, Chromosomes and Cancer 20 253-259.
38. Kohno T, Takahashi M, Manda R & Yokota J 1998 Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes, Chromosomes and Cancer 22 152-156.
39. Lee J, Park BJ, Park JH, Yang MH & Chi SG 1999a TGF-beta1 inhibition of apoptosis through the transcriptional up-regulation of Bcl-X(L) in human monocytic leukemia U937 cells. Experimental and Molecular Medicine 31 126-133.
40. Lee J-O, Yang H, Georgescu M-M, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P & Pavletich NP 1999b Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99 323-334.
41. Li D-M & Sun H 1997 TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor B. Cancer Research 57 2124-2129.
42. Li DM & Sun H 1998 PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. PNAS 95 15406-15411.
43. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittman M, Tycko B, Hibshoosh H, Wigler MH & Parsons R 1997 PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275 1943-1947.
44. Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks N & Parsons R 1998 The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Research 58 5667-5672.
45. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C & Parsons R 1997 Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genetics 16 64-67.
46. Liscovitch M & Cantley LC 1994 Lipid second messengers. Cell 77 329-334.
47. Liu W, James CD, Frederick L, Alderete BE & Jenkins RB 1997 PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Research 57 5254-5257.
48. Longy M, Coulon V, Duboue B, David A, Larregue M, Eng C, Amati P, Kraimps JL, Bottani A, Lacombe D & Bonneau D 1998 Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype. Journal of Medical Genetics 35 886-889.
49. Lynch ED, Ostermeyer EA, Lee MK, Arena JF, Ji H, Dann J, Swisshelm K, Suchard D, MacLeod PM, Kvinnsland S, Gjertsen BT, Heimdal K, Lubs H, Moller P & King MC 1997 Inherited mutations in PTEN that are associated with breast cancer, Cowden disease, and juvenile polyposis. American Journal of Human Genetics 61 1254-1260.
50. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M & Sellers WR 1999 Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Research 59 4291-4296.
51. Maehama T & Dixon JE 1999 PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends in Cell Biology 9 125-128.
52. Maier D, Jones G, Li X, Schonthal AH, Gratzl O, Van Meir EG & Merlo A 1999 The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Research 59 5479-5482.
53. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ & Eng C 1997a Germline mutations in PTEN are present in Bannayan-Zonana syndrome (letter). Nature Genetics 16 333-334.
54. Marsh DJ, Roth S, Lunetta KL, Hemminki A, Dahia PL, Sistonen P, Zheng Z, Caron S, van Orsouw NJ, Bodmer WF, Cottrell SE, Dunlop MG, Eccles D, Hodgson SV, Jarvinen H, Kellokumpu I, Markie D, Neale K, Phillips R, Rozen P, Syngal S, Vijg J, Tomlinson IP, Aaltonen LA & Eng C 1997b Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Research 57 5017-5021.
55. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboue B, Lin AY, Richardson AL, Bonnetblanc JM, Bressieux JM, Cabarrot-Moreau A, Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP, Gorlin RJ, Hodgson SV, Huson S, Lacombe D, Eng C et al. 1998a Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Human Molecular Genetics 7 507-515.
56. Marsh DJ, Dahia PL, Coulon V, Zheng Z, Dorion-Bonnet F, Call KM, Little R, Lin AY, Eeles RA, Goldstein AM, Hodgson SV, Richardson AL, Robinson BG, Weber HC, Longy M & Eng C 1998b Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes, Chromosomes and Cancer 21 61-69.
57. Marsh DJ, Dahia PLM, Caron S, Kum JB, Frayling IM, Tomlinson IPM, Hughes KS, Eeles RA, Hodgson SV, Murday VA, Houlston R & Eng C 1998c Germline PTEN mutations in Cowden syndrome-like families. Journal of Medical Genetics 35 881-885.
58. Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, Ahmed SF, Bodurtha J, Crowe C, Curtis MA, Dasouki M, Dünn T, Feit H, Geraghty MT, Graham Jr JM, Hodgson SV, Hunter A, Korf BR, Manchester D, Miesfeldt S, Murday VA, Nathanson KL, Parisi M, Pober B, Romano C, Tolmie JL, Trembath R, Winter RM, Zackai EH, Zori RT, Weng LP, Dahia PL & Eng C 1999 PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Human Molecular Genetics 8 1461-1472.
59. Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, Berchuck A & Futreal PA 1998 Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Research 58 2500-2503.
60. Mihaylova VT, Borland CZ, Manjarrez L, Stern MJ & Sun H 1999 The PTEN tumor suppressor homolog in Caenorhabditis elegans regulates longevity and dauer formation in an insulin receptor-like signaling pathway. PNAS 96 7427-7432.
61. Myers MP & Tonks NK 1997 PTEN: sometimes taking it off can be better than putting it on. American Journal of Human Genetics 61 1234-1238.
62. Myers MP, Stolarov J, Eng C, Li J, Wang SI, Wigler MH, Parsons R & Tonks NK 1997 PTEN, the tumor suppressor from human chromosome 10q23, is a dual specificity phosphatase. PNAS 94 9052-9057.
63. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP & Tonks NK 1998 The lipid phosphatase activity of PTEN is critical for its tumor supressor function. PNAS 95 13513-13518.
64. Nalefski EA & Falke JJ 1996 The C2 domain calcium-binding motif: structural and functional diversity. Protein Science 5 2375-2390.
65. Nelen MR, Padberg GW, Peeters EAJ, Lin AY, van den Helm B, Frants RR, Coulon V, Goldstein AM, van Reen MMM, Easton DF, Eeles RA, Hodgson S, Mulvihill JJ, Murday VA, Tucker MA, Mariman ECM, Starink TM, Ponder BAJ, Ropers HH, Kremer H, Longy M & Eng C 1996 Localization of the gene for Cowden disease to 10q22-23. Nature Genetics 13 114-116.
66. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, Lindboe CF, Fryns JP, Sijmons RH, Woods DG, Mariman EC, Padberg GW & Kremer H 1997 Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Human Molecular Genetics 6 1383-1387.
67. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ & Campbell IG 1998 Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Research 58 2095-2097.
68. Ogg S & Ruvkun G 1998 The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Molecular Cell 2 887-893.
69. Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA & Ruvkun G 1997 The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389 994-999.
70. Olschwang S, Serova-Sinilnikova OM, Lenoir GM & Thomas G 1998 PTEN germ-line mutations in juvenile polyposis coli (letter). Nature Genetics 18 12-14.
71. Perren A, Weng L-P, Boag A, Ziebold U, Thakore K, Dahia P, Komminoth P, Lees J, Mulligan L, Mutter G & Eng C 1999 Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. American Journal of Pathology 155 1253-1260.
72. Pfeifer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ & Goodfellow PJ 1995 Allelic loss of sequence from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Research 55 1922-1926.
73. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE & Parsons R 1999 Mutation of PTEN/Mmac1 in mice causes neoplasia in multiple organ systems. PNAS 96 1563-1568.
74. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM & Sellers WR 1999 Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/AKT pathway. PNAS 96 2110-2115.
75. Rasheed BKA, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD & Bigner SH 1995 Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 10 2243-2246.
76. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD & Bigner SH 1997 PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Research 57 4187-4190.
77. Risinger JI, Hayes AK, Berchuck A & Barrett JC 1997 PTEN/ MMAC1 mutations in endometrial cancers. Cancer Research 57 4736-4738.
78. Rohn JL, Hueber AO, McCarthy NJ, Lyon D, Navarro P, Burgering BM & Evan GI 1998 The opposing roles of the AKT and c-Myc signalling pathways in survival from CD95-mediated apoptosis. Oncogene 17 2811-2818.
79. Romashkova JA & Makarov SS 1999 NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401 86-90.
80. Rouault JP, Kuwabara PE, Sinilnikova OM, Duret L, Thierry-Mieg D & Billaud M 1999 Regulation of dauer larva development in Caenorhabditis elegans by daf-18, a homologue of the tumour suppressor PTEN. Current Biology 9 329-332.
81. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, Pelicci PG et al. 1992 Association of the She and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 360 689-692.
82. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penniger JM, Siderovski DP & Mak TW 1998 Negative regulation of PKB/AKT-dependent cell survival by the tumor suppressor PTEN. Cell 95 29-39.
83. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF & Tavtigian SV 1997 Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 15 356-362.
84. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X & Wu H 1999 PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and AKT/protein kinase B signaling pathway. PNAS 96 6199-6204.
85. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M & Mak TW 1998 High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Current Biology 8 1169-1178.
86. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R & Yamada KM 1998 Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280 1614-1617.
87. Tamura M, Gu J, Takino T & Yamada KM 1999 Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Research 59 442-449.
88. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R & Ellenson LH 1997 Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Research 57 3935-3940.
89. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Steck PA et al. 1997 MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Research 57 5221-5225.
90. Trybus TM, Burgess AC, Wojno KJ, Glover TW & Macoska JA 1996 Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Research 56 2263-2267.
91. Tsou HC, Teng DH, Ping XL, Brancolini V, Davis T, Hu R, Xie XX, Gruener AC, Schrager CA, Christiano AM, Eng C, Steck P, Ott J, Tavtigian SV & Peacocke M 1997 The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. American Journal of Human Genetics 61 1036-1043.
92. Tsou HC, Ping XL, Xie XX, Gruener AC, Zhang H, Nini R, Swisshelm K, Sybert V, Diamond TM, Sutphen R & Peacocke M 1998 The genetic basis of Cowden's syndrome: three novel mutations in PTEN/MMAC1/TEP1. Human Genetics 102 467-473.
93. Ueda K, Nishijima M, Inui H, Watatani M, Yayoi E, Okamura J, Yasutomi M, Nakamura Y & Miyoshi Y 1998 Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Japanese Journal of Cancer Research 89 17-21.
94. Vanhaesebroeck B, Leevers SJ, Panayotou G & Waterfield MD 1997 Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends in Biochemical Sciences 22 267-272.
95. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D & Parsons R 1997 Somatic mutations of PTEN in glioblastoma multiforme. Cancer Research 57 4183-4186.
96. Weng L-P, Smith WM, Dahia PLM, Ziebold U, Gil E, Lees JA & Eng C 1999 PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Research 59 5808-5814.
97. Whang YE, Wu X & Sawyers CL 1998a Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/ MMAC1 tumor suppressor gene. Journal of the National Cancer Institute 90 859-861.
98. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB & Sawyers CL 1998b Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. PNAS 95 5246-5250.
99. Wick W, Furnari FB, Naumann U, Cavenee WK & Weller M 1999 PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene 18 3936-3943.
100. Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, Wood J, Ross C, Sawyers CL & Whang YE 2000 Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. PNAS 97 4233-4238.
101. Yokomizo A, Tindall DJ, Hartmann L, Jenkins RB, Smith DI & Liu W 1998 Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer. International Journal of Oncology 13 101-105.
102. Zigman AF, Lavine JE, Jones MC, Boland CR & Carethers JM 1997 Localization of the Bannayan-Riley-Ruvalcaba syndrome gene to chromosome 10q23. Gastroenterology 113 1433-1437.